Tarsa Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tarsa Therapeutics, Inc.
Coronavirus Trend Helps Improve Krka’s EBIT By 85%
Slovenian firm Krka saw an increased demand for its prescription product portfolio during the quarter, which boosted group sales by more than a fifth. The company’s bottom line was a slightly more complex tale, as currency exposure in Russia wiped out significant gains in Krka’s EBIT.
Krka Finds Romanian Allegations Unjustified
Krka has denied giving its Romanian unit instructions to bribe healthcare professionals, following an internal investigation spurred by media reports of “irregularities” at the subsidiary.
Krka Responds To Romanian Allegations
Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.
Krka Vastly Expands Research Capacity
Slovenia’s Krka has inaugurated a €55.6m research and development centre that nearly doubles its R&D capabilities and will help drive new product launches.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.